CDTX Quote, Financials, Valuation and Earnings

Cogent Biosciences, Inc. has a net margin of -30201.66% compared to Cidara Therapeutics, Inc.'s net margin of --. Cidara Therapeutics, Inc.'s return on equity of -68.74% beat Cogent Biosciences, Inc.'s return on equity of -117.99%.

Cidara Therapeutics, Inc. has a consensus price target of $221.50, signalling upside risk potential of 0.05%. On the other hand Cogent Biosciences, Inc. has an analysts' consensus of $50.75 which suggests that it could grow by 36.87%. Given that Cogent Biosciences, Inc. has higher upside potential than Cidara Therapeutics, Inc., analysts believe Cogent Biosciences, Inc. is more attractive than Cidara Therapeutics, Inc..

Cidara Therapeutics, Inc. has a beta of 1.561, which suggesting that the stock is 56.074% more volatile than S&P 500. In comparison Cogent Biosciences, Inc. has a beta of 0.451, suggesting its less volatile than the S&P 500 by 54.923%.

Cidara Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cogent Biosciences, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cidara Therapeutics, Inc. pays -- of its earnings as a dividend. Cogent Biosciences, Inc. pays out -- of its earnings as a dividend.

Cidara Therapeutics, Inc. quarterly revenues are --, which are smaller than Cogent Biosciences, Inc. quarterly revenues of --. Cidara Therapeutics, Inc.'s net income of -$83.2M is lower than Cogent Biosciences, Inc.'s net income of -$80.9M. Notably, Cidara Therapeutics, Inc.'s price-to-earnings ratio is -- while Cogent Biosciences, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cidara Therapeutics, Inc. is 55.23x versus 55.99x for Cogent Biosciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Johnson & Johnson has a net margin of -30201.66% compared to Cidara Therapeutics, Inc.'s net margin of 20.83%. Cidara Therapeutics, Inc.'s return on equity of -68.74% beat Johnson & Johnson's return on equity of 33.27%.

Cidara Therapeutics, Inc. has a consensus price target of $221.50, signalling upside risk potential of 0.05%. On the other hand Johnson & Johnson has an analysts' consensus of $230.63 which suggests that it could fall by -3.9%. Given that Cidara Therapeutics, Inc. has higher upside potential than Johnson & Johnson, analysts believe Cidara Therapeutics, Inc. is more attractive than Johnson & Johnson.

Cidara Therapeutics, Inc. has a beta of 1.561, which suggesting that the stock is 56.074% more volatile than S&P 500. In comparison Johnson & Johnson has a beta of 0.350, suggesting its less volatile than the S&P 500 by 64.977%.

Cidara Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Johnson & Johnson offers a yield of 2.14% to investors and pays a quarterly dividend of $1.30 per share. Cidara Therapeutics, Inc. pays -- of its earnings as a dividend. Johnson & Johnson pays out 46.59% of its earnings as a dividend. Johnson & Johnson's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Cidara Therapeutics, Inc. quarterly revenues are --, which are smaller than Johnson & Johnson quarterly revenues of $24.6B. Cidara Therapeutics, Inc.'s net income of -$83.2M is lower than Johnson & Johnson's net income of $5.1B. Notably, Cidara Therapeutics, Inc.'s price-to-earnings ratio is -- while Johnson & Johnson's PE ratio is 21.73x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cidara Therapeutics, Inc. is 55.23x versus 6.19x for Johnson & Johnson. Usually stocks with elevated PS ratios are considered overvalued.

Merck & Co., Inc. has a net margin of -30201.66% compared to Cidara Therapeutics, Inc.'s net margin of 18.06%. Cidara Therapeutics, Inc.'s return on equity of -68.74% beat Merck & Co., Inc.'s return on equity of 39.63%.

Cidara Therapeutics, Inc. has a consensus price target of $221.50, signalling upside risk potential of 0.05%. On the other hand Merck & Co., Inc. has an analysts' consensus of $121.27 which suggests that it could fall by -0.54%. Given that Cidara Therapeutics, Inc. has higher upside potential than Merck & Co., Inc., analysts believe Cidara Therapeutics, Inc. is more attractive than Merck & Co., Inc..

Cidara Therapeutics, Inc. has a beta of 1.561, which suggesting that the stock is 56.074% more volatile than S&P 500. In comparison Merck & Co., Inc. has a beta of 0.280, suggesting its less volatile than the S&P 500 by 72.042%.

Cidara Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Merck & Co., Inc. offers a yield of 2.69% to investors and pays a quarterly dividend of $0.85 per share. Cidara Therapeutics, Inc. pays -- of its earnings as a dividend. Merck & Co., Inc. pays out 45.05% of its earnings as a dividend. Merck & Co., Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Cidara Therapeutics, Inc. quarterly revenues are --, which are smaller than Merck & Co., Inc. quarterly revenues of $16.4B. Cidara Therapeutics, Inc.'s net income of -$83.2M is lower than Merck & Co., Inc.'s net income of $3B. Notably, Cidara Therapeutics, Inc.'s price-to-earnings ratio is -- while Merck & Co., Inc.'s PE ratio is 16.76x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cidara Therapeutics, Inc. is 55.23x versus 4.70x for Merck & Co., Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer Inc. has a net margin of -30201.66% compared to Cidara Therapeutics, Inc.'s net margin of -9.34%. Cidara Therapeutics, Inc.'s return on equity of -68.74% beat Pfizer Inc.'s return on equity of 10.84%.

Cidara Therapeutics, Inc. has a consensus price target of $221.50, signalling upside risk potential of 0.05%. On the other hand Pfizer Inc. has an analysts' consensus of $28.71 which suggests that it could grow by 5.48%. Given that Pfizer Inc. has higher upside potential than Cidara Therapeutics, Inc., analysts believe Pfizer Inc. is more attractive than Cidara Therapeutics, Inc..

Cidara Therapeutics, Inc. has a beta of 1.561, which suggesting that the stock is 56.074% more volatile than S&P 500. In comparison Pfizer Inc. has a beta of 0.472, suggesting its less volatile than the S&P 500 by 52.751%.

Cidara Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer Inc. offers a yield of 6.32% to investors and pays a quarterly dividend of $0.43 per share. Cidara Therapeutics, Inc. pays -- of its earnings as a dividend. Pfizer Inc. pays out 126.47% of its earnings as a dividend.

Cidara Therapeutics, Inc. quarterly revenues are --, which are smaller than Pfizer Inc. quarterly revenues of $17.6B. Cidara Therapeutics, Inc.'s net income of -$83.2M is higher than Pfizer Inc.'s net income of -$1.6B. Notably, Cidara Therapeutics, Inc.'s price-to-earnings ratio is -- while Pfizer Inc.'s PE ratio is 20.09x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cidara Therapeutics, Inc. is 55.23x versus 2.48x for Pfizer Inc.. Usually stocks with elevated PS ratios are considered overvalued.